Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P-Reference-Cited by-同舟云学术

Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P

Published:2017-07-18 Issue:33 Volume:8 Page:55204-55215
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Liu Yewei¹²³⁴,Yin Ting¹,Keyzer Frederik De¹,Feng Yuanbo¹,Chen Feng¹,Liu Jianjun²,Song Shaoli²,Yu Jie¹,Vandecaveye Vincent¹,Swinnen Johan¹,Bormans Guy¹,Himmelreich Uwe¹,Oyen Raymond¹,Zhang Jian⁵,Huang Gang²³⁴,Ni Yicheng¹⁵

Affiliation:

1. Biomedical Group, Campus Gasthuisberg, KU Leuven, Leuven 3000, Belgium

2. Institute of Clinical Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

3. Shanghai University of Medicine and Health Sciences, Shanghai 201318, China

4. Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine (SJTUSM) and Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai 200025, China

5. Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An emerging technique for the dual‑targeting chemo‑radio‑ablation of generic micro‑cancers in conjunction with cancer liquid biopsy;Oncology Reports;2022-12-23

2. Treatment Effect of a Vascular-Disrupting Agent Dynamically Monitored by DWI: An Animal Experimental Study;Canadian Journal of Gastroenterology and Hepatology;2021-12-30

3. Vascular disrupting agents in cancer therapy;European Journal of Pharmacology;2021-01

4. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation;Diagnostics;2020-01-31

5. Predicting Therapeutic Efficacy of Vascular Disrupting Agent CA4P in Rats with Liver Tumors by Hepatobiliary Contrast Agent Mn-DPDP-Enhanced MRI;Translational Oncology;2020-01